Predicting longer-term progression-free survival (PFS) with durvalumab after chemoradiotherapy (CRT) in unresectable stage III NSCLC using a mixture cure model (MCM)

被引：1
|
作者：
Faivre-Finn, C. [1 ,2 ]
Jackson, D. [3 ]
Abrams, K. R. [4 ]
Hawkins, N. S. [5 ]
Thiyagarajah, P. [3 ]
Zhang, Y. [6 ]
Hettle, R. [3 ]
Dunlop, W. [3 ]
Spigel, D. R. [7 ]
机构：
[1] Univ Manchester, Manchester, Lancs, England
[2] Christie NHS Fdn Trust, Manchester, Lancs, England
[3] AstraZeneca, Cambridge, England
[4] Univ Warwick, Dept Stat, Coventry, W Midlands, England
[5] Univ Glasgow, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland
[6] AstraZeneca, Gaithersburg, MD USA
[7] Sarah Cannon Res Inst Tennessee Oncol, Med Oncol, Nashville, TN USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.10.102
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
84P
引用
收藏
页码：S1408 / S1409
页数：2
相关论文
共 30 条
  • [21] Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R
    Filippi, A. R.
    Bar, J.
    Chouaid, C.
    Christoph, D. C.
    Field, J. K.
    Fietkau, R.
    Garassino, M. C.
    Garrido, P.
    Haakensen, V. D.
    Kao, S.
    Markman, B.
    Mcdonald, F.
    Mornex, F.
    Moskovitz, M.
    Peters, S.
    Sibille, A.
    Siva, S.
    Heuvel, M. van den
    Vercauter, P.
    Anand, S.
    Chander, P.
    Licour, M.
    Lima, A. R. de
    Qiao, Y.
    Girard, N.
    ESMO OPEN, 2024, 9 (06)
  • [22] Al Serial Image Prediction of Progression-Free Survival (PFS) for Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC) Patients Treated with Chemoradiation (CRT) and Durvalumab Consolidation
    Veeraraghavan, H.
    Jiang, J.
    Jee, J.
    Lebow, E. S.
    Deasy, J. O.
    Rimner, A.
    Shaverdian, N.
    Yu, H.
    Gomez, D. R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E68 - E68
  • [23] Using minimal residual disease to move towards cure: A mathematical model predicting progression-free survival and cure rate based on end-of treatment MRD level
    Gregory, Walter
    Rawstron, Andy
    Munir, Talha
    Collett, Laura
    Cohen, Dena
    Hillmen, Peter
    LEUKEMIA & LYMPHOMA, 2015, 56 : 130 - 130
  • [24] Early recovery of leukocyte subsets is associated with favorable progression-free survival in patients with inoperable stage II/III NSCLC after multimodal treatment: a prospective explorative study
    Hofer, Thomas P.
    Nieto, Alexander E.
    Kaesmann, Lukas
    Pelikan, Carolyn J.
    Taugner, Julian
    Mathur, Saloni
    Eze, Chukwuka
    Belka, Claus
    Manapov, Farkhad
    Noessner, Elfriede
    RADIATION ONCOLOGY, 2025, 20 (01)
  • [25] Development and validation of an [18F]FDG-PET/CT radiomic model for predicting progression-free survival for patients with stage II - III thoracic esophageal squamous cell carcinoma who are treated with definitive chemoradiotherapy
    Takahashi, Noriyoshi
    Tanaka, Shohei
    Umezawa, Rei
    Takanami, Kentaro
    Takeda, Kazuya
    Yamamoto, Takaya
    Suzuki, Yu
    Katsuta, Yoshiyuki
    Kadoya, Noriyuki
    Jingu, Keiichi
    ACTA ONCOLOGICA, 2023, 62 (02) : 159 - 165
  • [26] Development and validation of a prediction model using molecular marker for long-term survival in unresectable stage III non-small cell lung cancer treated with chemoradiotherapy
    Yang, Yufan
    Zhang, Tao
    Zhou, Zongmei
    Liang, Jun
    Chen, Dongfu
    Feng, Qinfu
    Xiao, Zefen
    Hui, Zhouguang
    Lv, Jima
    Deng, Lei
    Wang, Xin
    Wang, Wenqing
    Wang, Jianyang
    Liu, Wenyang
    Zhai, Yirui
    Wang, Jie
    Bi, Nan
    Wang, Luhua
    THORACIC CANCER, 2022, 13 (03) : 296 - 307
  • [27] Radiotherapy (RT) patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients (pts) with Stage III unresectable non-small cell lung cancer (UR-NSCLC) treated with durvalumab (D) after chemoradiotherapy (CRT)
    Filippi, A. R.
    Bar, J.
    Christoph, D. C.
    Field, J. K.
    Fietkau, R.
    Garassino, M. C.
    Garrido Lopez, P.
    Haakensen, V. D.
    Kao, S. C-H.
    McDonald, F.
    Mornex, F.
    Moskovitz, M.
    Peters, S.
    van den Heuvel, M.
    Vercauter, P.
    Smit, H. J. M.
    Chander, P.
    Qiao, Y.
    Faria, J.
    Girard, N.
    ANNALS OF ONCOLOGY, 2024, 35 : S798 - S799
  • [28] A BAYESIAN HIERARCHICAL MIXTURE CURE MODELLING (MCM) FRAMEWORK FOR THE JOINT UTILIZATION OF PROGRESSION FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN ESTIMATING LONG-TERM SURVIVORSHIP RATES IN PREVIOUSLY UNTREATED METASTATIC MELANOMA: A CASE STUDY FROM CHECKMATE-067 TRIAL
    Green, N.
    Paly, V
    Youn, J. H.
    Kurt, M.
    Moshyk, A.
    Baio, Gianluca G.
    VALUE IN HEALTH, 2022, 25 (01) : S10 - S11
  • [29] Osimertinib after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable (UR) stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC): Post-progression outcomes from the phase III LAURA study
    Ozguroglu, M.
    Ahn, M-J.
    Dong, X.
    Yang, J. C-H.
    Oizumi, S.
    Goto, K.
    Cobo Dols, M.
    Kim, S-W.
    Hsia, T-C.
    Chindaprasirt, J.
    Fujiki, F. K.
    Valdiviezo, N.
    Poole, L.
    Evans, A. L.
    Armenteros Monterroso, E.
    Lu, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S1626 - S1626
  • [30] p Durvalumab impacts progression-free survival while high-dose radiation > 66 Gy improves local control without excess toxicity in unresectable NSCLC stage III: Real-world data from the A ustrian radio-oncologica l l ung cancer st udy a ssociation r egistry (ALLSTAR)
    Zehentmayr, Franz
    Feurstein, Petra
    Ruznic, Elvis
    Langer, Brigitte
    Grambozov, Brane
    Klebermass, Marisa
    Huepfel, Herbert
    Feichtinger, Johann
    Minasch, Danijela
    Heilmann, Martin
    Breitfelder, Barbara
    Steffal, Claudia
    Gastinger-Grass, Gisela
    Kirchhammer, Karoline
    Kazil, Margit
    Stranzl, Heidi
    Dieckmann, Karin
    RADIOTHERAPY AND ONCOLOGY, 2024, 196
123